Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

  • Posted on 25 July, 2025
    A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
    Read more

    Rapid repetitive syllable sounds associate with episodic memory, executive function, and working memory in cognitively healthy and subjectively impaired older adults

    • Posted on 21 July, 2025
      Could a 10-second speech test repeating “pa,” “ta,” “ka” be the key to earlier detection of Alzheimer’s risk? Our new...
      Read more

      What can speech tell us about pain?

      • Posted on 26 June, 2025
        Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
        Read more